Aardvark Therapeutics, Inc.
AARD
$8.49
-$0.50-5.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.44% | 95.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 51.37% | 10.79% | |||
| Operating Income | -51.37% | -10.79% | |||
| Income Before Tax | -54.32% | -6.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -54.32% | -6.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -54.32% | -6.05% | |||
| EBIT | -51.37% | -10.79% | |||
| EBITDA | -51.33% | -10.83% | |||
| EPS Basic | 6.12% | 67.34% | |||
| Normalized Basic EPS | 6.02% | 67.22% | |||
| EPS Diluted | 6.12% | 67.34% | |||
| Normalized Diluted EPS | 6.02% | 67.22% | |||
| Average Basic Shares Outstanding | 64.39% | 224.75% | |||
| Average Diluted Shares Outstanding | 64.39% | 224.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||